Residency · Jacksonville, FL
Sponsored by Mayo Clinic College of Medicine and Science
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
Lancet (London, England) · 2025 · 44 citations · Jason Sluzevich
The impact of reactive oxygen species in the development of cardiometabolic disorders: a review.
Lipids in health and disease · 2021 · 107 citations · Ayodeji Ajayi
Squamous-Cell Carcinoma of the Skin.
The New England journal of medicine · 2023 · 78 citations · Ashley Wysong
Health Disparities, Clinical Trials, and the Digital Divide.
Mayo Clinic proceedings · 2023 · 60 citations · Olayemi Sokumbi
riSCC: A personalized risk model for the development of poor outcomes in cutaneous squamous cell carcinoma.
Journal of the American Academy of Dermatology · 2025 · 20 citations · Ashley Wysong
Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Journal of the American Academy of Dermatology · 2023 · 72 citations · Jordan Phillipps
Impact of immunosuppression on cutaneous squamous cell carcinoma outcomes.
Journal of the American Academy of Dermatology · 2026 · 8 citations · Ashley Wysong
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma.
Journal of the American Academy of Dermatology · 2021 · 79 citations · Ashley Wysong